Enhanced antibody production in mice to the malaria antigen AMA 1 by CPG 7909 requires physical association of CpG and antigen

被引：26

作者：

Mullen, Gregory E. D. ^{[1
]}

Aebig, Joan A. ^{[1
]}

Dobrescu, Gelu ^{[1
]}

Rausch, Kelly ^{[1
]}

Lambert, Lynn ^{[1
]}

Long, Carole A. ^{[1
]}

Miles, Aaron P. ^{[1
]}

Saul, Allan ^{[1
]}

机构：

[1] NIAID, NIH, Malaria Vaccine Dev Branch, Rockville, MD 20852 USA

来源：

VACCINE | 2007年 / 25卷 / 29期

关键词：

vaccine; formulation; malaria antigen; CPG; 7909; antibody response;

D O I：

10.1016/j.vaccine.2007.05.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

CpG oligodeoxynucleotides are potent immunostimulants. In this study, CPG 7909 was formulated with the recombinant Plasmodium falciparum protein AMA1-C1 adsorbed to Alhydrogel (aluminum hydroxide) and used to immunize mice. Mice receiving free CPG 7909 in a separate same site injection to the AMA1-C1/Alhydrogel had the same antibody responses as mice receiving AMA1 -C1/Alhydrogel alone. For mice immunized with CPG 7909 bound to the AMA1-C1/Alhydrogel formulation, there was a bell shaped CPG 7909 dose-response curve with the highest antibody response co-incident with the concentration of CPG 7909 that saturated binding to the Alhydrogel. At a higher CPG 7909 dose where 74% was unbound, there was no enhancement of response over AMA1-C1/Alhydrogel alone. Our results suggest that the adjuvant effects of CpGs are optimal when adsorbed to Alhydrogel and highlight the need for careful characterization of the vaccine formulation. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：5343 / 5347

页数：5

共 15 条

[1] CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in anti retroviral-treated HIV-infected adults [J].

Cooper, CL ;

Davis, HL ;

Angel, JB ;

Morris, ML ;

Elfer, SM ;

Seguin, I ;

Krieg, AM ;

Cameron, DW .

AIDS, 2005, 19 (14) :1473-1479

[2] CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults:: A double-blind phase I/II study [J].

Cooper, CL ;

Davis, HL ;

Morris, ML ;

Efler, SM ;

Al Adhami, M ;

Krieg, AM ;

Cameron, DW ;

Heathcote, J .

JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (06) :693-701

[3] Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine [J].

Cooper, CL ;

Davis, HL ;

Morris, ML ;

Efler, SM ;

Krieg, AM ;

Li, Y ;

Laframboise, C ;

Al Adhami, MJ ;

Khaliq, Y ;

Seguin, I ;

Cameron, DW .

VACCINE, 2004, 22 (23-24) :3136-3143

[4] Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo [J].

Hartmann, G ;

Weeratna, RD ;

Ballas, ZK ;

Payette, P ;

Blackwell, S ;

Suparto, I ;

Rasmussen, WL ;

Waldschmidt, M ;

Sajuthi, D ;

Purcell, RH ;

Davis, HL ;

Krieg, AM .

JOURNAL OF IMMUNOLOGY, 2000, 164 (03) :1617-1624

[5] A Toll-like receptor recognizes bacterial DNA [J].

Hemmi, H ;

Takeuchi, O ;

Kawai, T ;

Kaisho, T ;

Sato, S ;

Sanjo, H ;

Matsumoto, M ;

Hoshino, K ;

Wagner, H ;

Takeda, K ;

Akira, S .

NATURE, 2000, 408 (6813) :740-745

[6] In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1):: Production and activity of an AMA1 vaccine and generation of a multiallelic response [J].

Kennedy, MC ;

Wang, J ;

Zhang, YL ;

Miles, AP ;

Chitsaz, F ;

Saul, A ;

Long, CA ;

Miller, LH ;

Stowers, AW .

INFECTION AND IMMUNITY, 2002, 70 (12) :6948-6960

[7] Use of CpG oligodeoxynucleotides as immune adjuvants [J].

Klinman, DM ;

Currie, D ;

Gursel, I ;

Verthelyi, D .

IMMUNOLOGICAL REVIEWS, 2004, 199 (01) :201-216

[8] CPG MOTIFS IN BACTERIAL-DNA TRIGGER DIRECT B-CELL ACTIVATION [J].

KRIEG, AM ;

YI, AK ;

MATSON, S ;

WALDSCHMIDT, TJ ;

BISHOP, GA ;

TEASDALE, R ;

KORETZKY, GA ;

KLINMAN, DM .

NATURE, 1995, 374 (6522) :546-549

[9] Phase 1 clinical trial of apical membrane antigen 1:: an asexual blood-stage vaccine for Plasmodium falciparum malaria [J].

Malkin, EM ;

Diemert, DJ ;

McArthur, JH ;

Perreault, JR ;

Miles, AP ;

Giersing, BK ;

Mullen, GE ;

Orcutt, A ;

Muratova, O ;

Awkal, M ;

Zhou, H ;

Wang, J ;

Stowers, A ;

Long, CA ;

Mahanty, S ;

Miller, LH ;

Saul, A ;

Durbin, AP .

INFECTION AND IMMUNITY, 2005, 73 (06) :3677-3685

[10] Montanide® ISA 720 vaccines:: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations [J].

Miles, AP ;

McClellan, HA ;

Rausch, KM ;

Zhu, DM ;

Whitmore, MD ;

Singh, S ;

Martin, LB ;

Wu, YM ;

Giersing, BK ;

Stowers, AW ;

Long, CA ;

Saul, A .

VACCINE, 2005, 23 (19) :2530-2539

← 1 2 →